The company said, “Revenue for the full year 2025 is expected to be in the range of $45.5 million to $47.5 million, representing growth of 67% to 75% over 2024.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARL:
- CVS Health upgraded, Occidental downgraded: Wall Street’s top analyst calls
- Carlsmed initiated with a Buy at Truist
- Buy Rating for Carlsmed: Innovative Aprevo Technology and Strong Growth Projections Justify Premium Valuation
- Carlsmed initiated with a Buy at BofA
- Carlsmed initiated with a Buy at BTIG